Hims & Hers Health, Inc. Under Investigation Following Legal Issues
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 21 2026
0mins
Should l Buy HIMS?
Source: PRnewswire
- Investigation Launched: Kahn Swick & Foti, LLC has initiated an investigation into Hims & Hers Health, Inc., focusing on whether its executives breached fiduciary duties to shareholders, which could impact corporate governance.
- Partnership Termination Impact: Novo Nordisk announced the termination of its partnership with Hims in June 2025, citing the company's failure to comply with laws, potentially jeopardizing patient safety and severely damaging its market reputation.
- Securities Lawsuit Progress: Hims & Hers and its executives are facing a securities class action lawsuit for failing to disclose material information, with the court denying the company's motion to dismiss, allowing the case to proceed and potentially resulting in significant financial liabilities.
- Investor Rights at Risk: KSF is urging long-term holders of Hims shares to provide information, indicating that the legal issues facing the company could significantly affect investor rights and increase investment risks.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 19.500
Low
16.50
Averages
32.95
High
60.00
Current: 19.500
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hims & Hers Faces Legal Investigation and Lawsuit
- Legal Investigation Launched: The Schall Law Firm has announced an investigation into Hims & Hers Health, Inc. for potential violations of securities laws, focusing on whether the company made false or misleading statements that could undermine investor confidence.
- FDA Statement Impact: The FDA has indicated it will take decisive steps to restrict the use of GLP-1 active pharmaceutical ingredients, which could significantly negatively impact Hims & Hers' market sales, particularly in the non-FDA-approved compounded drug sector.
- Increased Litigation Risk: Novo Nordisk has filed a lawsuit against Hims & Hers seeking to bar the sale of compounded weight loss drugs, which adds to the company's legal risks and could adversely affect its financial performance.
- Significant Stock Price Drop: On February 9, 2026, shares of Hims & Hers fell by more than 17.8% during trading, reflecting market concerns about the company's future prospects and a decline in investor confidence.
See More
HIMS & HERS: BOFA Global Research Lowers Price Target to $21.00 from $23.00
- Price Reduction Announcement: HIMS & HERS has announced a price cut for its services, reducing the cost from $23.00 to $21.00.
- Impact on Consumers: This price adjustment aims to make healthcare services more accessible to consumers, potentially increasing customer engagement and satisfaction.
See More
Hims Partners with Novo Nordisk for Wegovy Rollout
- Prescription Target Increase: CEO Andrew Dudum announced that Hims & Hers Health Inc. is on track to deliver over 100,000 Wegovy prescriptions monthly, marking a strategic shift in its weight-loss business that is expected to attract more customers and enhance market share.
- Diverse Medication Options: Under the agreement with Novo Nordisk, Hims will offer multiple Wegovy injection doses (ranging from 0.25 mg to 2.4 mg) and oral formulations, catering to various patient needs, thereby enhancing customer loyalty and satisfaction.
- Increased Shareholder Confidence: CFO Yemi Okupe disclosed plans to sell approximately 240,560 shares worth about $4.89 million under a Rule 10b5-1 trading plan, indicating management's confidence in future growth and reflecting a positive outlook on market opportunities.
- Rising Market Optimism: Despite a nearly 30% decline in HIMS stock over the past year, Barclays raised its price target to $29, believing that the partnership with Novo Nordisk eliminates legal uncertainties and signals expanding opportunities tied to new product launches.
See More
New Derivative Income ETFs Pose Unnecessary Risks
High Yield ETF: An exchange-traded fund (ETF) linked to Hims & Hers Health offers an enticing 80% yield.
Investment Temptation: The potential for high returns may attract investors despite the underlying product's association with erectile dysfunction.
See More
The 'Diabesity' Market Is Poised for Rapid Growth: Key Catalysts for Lilly and Novo Stocks.
Weight-loss Drugs in Focus: The spotlight is on weight-loss drugs, particularly GLP-1 medications like Wegovy and Zepbound, as they gain popularity.
Market Competition: Eli Lilly and Novo Nordisk are key players in the emerging "diabesity" market, indicating a competitive landscape ahead.
See More
Hims CFO Plans to Sell $4.89 Million in Shares
- Executive Sell-off Plan: Hims & Hers CFO Oluyemi Okupe plans to sell up to 240,560 shares valued at approximately $4.89 million, which may raise concerns about the company's future confidence among investors.
- Stock Performance Volatility: Despite HIMS stock rising over 6% on Monday before the insider sale announcement, it fell 1% in premarket trading after the disclosure, indicating investor sensitivity to insider selling.
- New Product Launch: Hims recently launched a lineup of Novo Nordisk GLP-1 therapies, including FDA-approved Wegovy injections and various pill formulations, aimed at expanding its weight-loss platform, although the insider sale could impact market acceptance of these new products.
- Market Sentiment Deterioration: According to Stocktwits, retail sentiment for HIMS is bearish with extremely low message volume, reflecting investor unease about the company's future, particularly in light of the executive sell-off.
See More
Hims & Hers Faces Legal Investigation and Lawsuit
- Legal Investigation Launched: The Schall Law Firm has announced an investigation into Hims & Hers Health, Inc. for potential violations of securities laws, focusing on whether the company made false or misleading statements that could undermine investor confidence.
- FDA Statement Impact: The FDA has indicated it will take decisive steps to restrict the use of GLP-1 active pharmaceutical ingredients, which could significantly negatively impact Hims & Hers' market sales, particularly in the non-FDA-approved compounded drug sector.
- Increased Litigation Risk: Novo Nordisk has filed a lawsuit against Hims & Hers seeking to bar the sale of compounded weight loss drugs, which adds to the company's legal risks and could adversely affect its financial performance.
- Significant Stock Price Drop: On February 9, 2026, shares of Hims & Hers fell by more than 17.8% during trading, reflecting market concerns about the company's future prospects and a decline in investor confidence.
See More
HIMS & HERS: BOFA Global Research Lowers Price Target to $21.00 from $23.00
- Price Reduction Announcement: HIMS & HERS has announced a price cut for its services, reducing the cost from $23.00 to $21.00.
- Impact on Consumers: This price adjustment aims to make healthcare services more accessible to consumers, potentially increasing customer engagement and satisfaction.
See More
Hims Partners with Novo Nordisk for Wegovy Rollout
- Prescription Target Increase: CEO Andrew Dudum announced that Hims & Hers Health Inc. is on track to deliver over 100,000 Wegovy prescriptions monthly, marking a strategic shift in its weight-loss business that is expected to attract more customers and enhance market share.
- Diverse Medication Options: Under the agreement with Novo Nordisk, Hims will offer multiple Wegovy injection doses (ranging from 0.25 mg to 2.4 mg) and oral formulations, catering to various patient needs, thereby enhancing customer loyalty and satisfaction.
- Increased Shareholder Confidence: CFO Yemi Okupe disclosed plans to sell approximately 240,560 shares worth about $4.89 million under a Rule 10b5-1 trading plan, indicating management's confidence in future growth and reflecting a positive outlook on market opportunities.
- Rising Market Optimism: Despite a nearly 30% decline in HIMS stock over the past year, Barclays raised its price target to $29, believing that the partnership with Novo Nordisk eliminates legal uncertainties and signals expanding opportunities tied to new product launches.
See More
New Derivative Income ETFs Pose Unnecessary Risks
High Yield ETF: An exchange-traded fund (ETF) linked to Hims & Hers Health offers an enticing 80% yield.
Investment Temptation: The potential for high returns may attract investors despite the underlying product's association with erectile dysfunction.
See More
The 'Diabesity' Market Is Poised for Rapid Growth: Key Catalysts for Lilly and Novo Stocks.
Weight-loss Drugs in Focus: The spotlight is on weight-loss drugs, particularly GLP-1 medications like Wegovy and Zepbound, as they gain popularity.
Market Competition: Eli Lilly and Novo Nordisk are key players in the emerging "diabesity" market, indicating a competitive landscape ahead.
See More
Hims CFO Plans to Sell $4.89 Million in Shares
- Executive Sell-off Plan: Hims & Hers CFO Oluyemi Okupe plans to sell up to 240,560 shares valued at approximately $4.89 million, which may raise concerns about the company's future confidence among investors.
- Stock Performance Volatility: Despite HIMS stock rising over 6% on Monday before the insider sale announcement, it fell 1% in premarket trading after the disclosure, indicating investor sensitivity to insider selling.
- New Product Launch: Hims recently launched a lineup of Novo Nordisk GLP-1 therapies, including FDA-approved Wegovy injections and various pill formulations, aimed at expanding its weight-loss platform, although the insider sale could impact market acceptance of these new products.
- Market Sentiment Deterioration: According to Stocktwits, retail sentiment for HIMS is bearish with extremely low message volume, reflecting investor unease about the company's future, particularly in light of the executive sell-off.
See More
